Virginia Tech spinout Landos Biopharma priced its shares at $16 to raise $100m and will use proceeds to advance the development of two treatments for inflammatory bowel disease.

Landos Biopharma, a US-based autoimmune disease treatments developer based on research at Virginia Tech, issued nearly 6.3 million shares priced at $16 on Wednesday to raise $100m in its initial public offering.
The pricing marks the midpoint of a $15 to $17 range and gave Landos a market value of $650m. It began trading on the Nasdaq Global Select Market yesterday using the ticker symbol LABP, with shares dropping to $12.50 at close.
Founded in 2017, Landos…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in